Analyst Price Targets — ABT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 11:06 am | — | Piper Sandler | $118.00 | $98.82 | TheFly | Abbott price target raised to $118 from $115 at Piper Sandler |
| July 16, 2026 8:00 pm | — | BTIG | $134.00 | $98.82 | StreetInsider | Abbott Labs (ABT) PT Raised to $134 at BTIGMember Login |
| July 6, 2026 12:39 pm | Vijay Kumar | Evercore ISI | $112.00 | $93.64 | TheFly | Abbott price target lowered to $112 from $120 at Evercore ISI |
| June 30, 2026 8:18 pm | David Rescott | Robert W. Baird | $121.00 | $90.68 | TheFly | Abbott initiated with an Outperform at Baird |
| April 22, 2026 12:25 am | — | Daiwa | $92.00 | $92.75 | TheFly | Abbott downgraded to Neutral from Outperform at Daiwa |
| April 20, 2026 9:47 am | Matt Miksic | Barclays | $143.00 | $96.83 | TheFly | Abbott price target lowered to $143 from $144 at Barclays |
| April 17, 2026 11:52 am | — | UBS | $115.00 | $95.46 | TheFly | Abbott price target lowered to $115 from $132 at Oppenheimer |
| April 17, 2026 11:33 am | — | Piper Sandler | $115.00 | $95.46 | TheFly | Abbott price target lowered to $115 from $135 at Piper Sandler |
| April 17, 2026 10:49 am | — | Stifel Nicolaus | $120.00 | $95.46 | TheFly | Abbott price target lowered to $120 from $145 at Stifel |
| March 13, 2026 1:37 pm | Danielle Antalffy | UBS | $158.00 | $108.42 | StreetInsider | UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability |
Latest News for ABT
ABT's diversified diagnostics/nutrition/medtech segments drive multi-pronged growth prospects, as the management targets a +7% organic growth rate. The recent EXAS acquisition introduces balance sheet/bottom-line risks, albeit with the new Cancer Diagnostic segment delivering double-digit growth rates. The prior meltdown unlocks the cheap valuations, the richer dividend yields, and the excellent upside potential to…
Abbott Laboratories is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Friday, adding that its operations were not affected.
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
Abbott Laboratories (NYSE:ABT) reported upbeat second-quarter results and raised its full-year adjusted earnings outlook on Thursday.
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company’s...
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.